CD19 and B-cell non-Hodgkin lymphoma: The result of a clinical trial with CD19-targeted CAR-NK cell therapy by UCB-derived CAR-NK cells for 11 patients with CD19 positive B cell lymphoma and CLL has recently demonstrated promising clinical efficacy, feasibility, and safety profiles.